Supplementary Material for: GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-analysis of Incidence, Risk, Subtypes, and Mechanisms

GLP-1 receptor agonists (GLP-1 RAs) are linked to a 40% increased risk of non-scarring alopecia, as shown in a meta-analysis of 17 studies with 1,091,743 patient-exposures. The study found significant associations with telogen effluvium and androgenetic alopecia, particularly with the use of semaglutide and tirzepatide. Interestingly, 58% of patients with central centrifugal cicatricial alopecia experienced improvement. The increased risk is mainly due to weight loss-induced micronutrient deficiency. Dermatologists are advised to counsel patients on this risk and avoid stopping the medication prematurely.